Company Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra 16:35:18 21/06/2024 BST 5-day change 1st Jan Change
8.33 EUR -0.30% Intraday chart for Evotec SE -0.83% -60.86%

Business Summary

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Number of employees: 5,055

Sales per Business

EUR in Million2022Weight2023Weight Delta
EVT Execute
65.8 %
547 72.8 % 515 65.8 % -5.89%
EVT Innovate
34.2 %
205 27.2 % 267 34.2 % +30.36%

Sales per region

EUR in Million2022Weight2023Weight Delta
United States
59.5 %
418 55.7 % 459 59.5 % +9.83%
Rest of the World
12.3 %
127 16.9 % 95 12.3 % -24.91%
United Kingdom
11.2 %
115 15.3 % 86 11.2 % -25.06%
Switzerland
8.4 %
-- 65 8.4 % -
Germany
4.4 %
59 7.8 % 34 4.4 % -42.04%
France
4.1 %
32 4.3 % 32 4.1 % -0.83%

Managers

Managers TitleAgeSince
Chief Executive Officer 61 18/06/19
Director of Finance/CFO 51 06/02/23
Chief Operating Officer 54 30/04/12
Chief Tech/Sci/R&D Officer 60 31/08/10
Public Communications Contact - -
Investor Relations Contact - -
Corporate Officer/Principal 51 30/04/22

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 61 18/06/19
Director/Board Member 56 18/06/19
Chairman 63 16/06/14
Director/Board Member 41 21/06/22
Director/Board Member 62 31/05/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 177,542,097 160,931,634 ( 90.64 %) 249,915 ( 0.1408 %) 90.64 %

Shareholders

NameEquities%Valuation
T. Rowe Price International Ltd.
9.792 %
17,384,316 9.792 % 163 M €
Novo Holdings A/S (Investment Company)
8.410 %
14,931,858 8.410 % 140 M €
Mubadala Investment Co. (Investment Company)
6.467 %
11,481,503 6.467 % 108 M €
2,904,146 1.636 % 27 M €
1,514,826 0.8532 % 14 M €
Franklin Bissett Investment Management
0.7322 %
1,300,000 0.7322 % 12 M €
Lupus alpha Asset Management AG
0.4833 %
858,000 0.4833 % 8 M €
Amundi Asset Management SA (Investment Management)
0.3030 %
537,880 0.3030 % 5 M €
Metzler Asset Management GmbH
0.2631 %
467,030 0.2631 % 4 M €
BNP Paribas Asset Management Belgium SA
0.2573 %
456,902 0.2573 % 4 M €
NameEquities%Valuation
Mubadala Investment Co. (Investment Company)
5.179 %
4,597,701 5.179 % 22 M €
Morgan Stanley Capital Services LLC
0.0987 %
87,606 0.0987 % 409 996 €
Millennium Management LLC
0.0933 %
82,815 0.0933 % 387 574 €
DCF Advisers LLC
0.0538 %
47,797 0.0538 % 223 690 €
Optiver Holding BV
0.0468 %
41,507 0.0468 % 194 253 €
Aperio Group LLC
0.0424 %
37,600 0.0424 % 175 968 €
Cetera Investment Advisers LLC
0.0276 %
24,543 0.0276 % 114 861 €
Adar1 Capital Management LLC
0.008674 %
7,700 0.008674 % 36 036 €
Quadrant Capital Group LLC
0.007104 %
6,306 0.007104 % 29 512 €
U.S. Trust Company of Delaware
0.004597 %
4,081 0.004597 % 19 099 €

Holdings

NameEquities%Valuation
14,035,200 11.86% 74,386,560 $

Company contact information

Evotec SE

Manfred Eigen Campus Essener Bogen 7

22419, Hamburg

+49 40 560 81 0

http://evotec.com
address Evotec SE(EVT)

Group companies

NameCategory and Sector
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Miscellaneous Commercial Services
Pharmaceuticals: Major